Evidence map›Paper›PMID 27464822›Full record

Trial reportBMC cancer2016

Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment.

Theresa Vilsmaier, Brigitte Rack, Wolfgang Janni, Udo Jeschke, Tobias Weissenbacher, SUCCESS Study Group

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02181101 (Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02181101 phase3completednot on this map

Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial

TypeinterventionalSponsorLudwig-Maximilians - University of MunichRan2005 to 2013Enrolled3,754ConditionsBreast NeoplasmsArmsFEC-DocGemzar adjuvant chemotherapy, FEC-Doc adjuvant chemotherapy, Zoledronic acid i.v. 2 years, Zoledronic acid i.v. 5 years
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Theresa VilsmaierDepartment of Obstetrics and Gynecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337, Munich, Germany.
Brigitte RackDepartment of Obstetrics and Gynecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337, Munich, Germany.
Wolfgang JanniDepartment of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Udo JeschkeDepartment of Obstetrics and Gynecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337, Munich, Germany. udo.jeschke@med.uni-muenchen.de.ORCID 0000-0003-2623-3235
Tobias WeissenbacherDepartment of Obstetrics and Gynecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337, Munich, Germany.
SUCCESS Study Group
Ludwig-Maximilians-Universität München · DEUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating tumour cells (CTCs) have been found to be a prognostic marker for reduced disease free survival, breast cancer-specific survival, and overall survival before the start of systemic treatment.

methodsA total of 200 patients' sera were included in this study, 100 patients being CTC positive and 100 patients being CTC negative. Matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification and survived breast cancer patients vs. deceased tumor associated patients. A multi cytokine/chemokine array was used to screen the sera for the angiogenic markers.

resultsStatistical significant correlation was exposed for sFlt1 values in regard to the CTC-Status. CTC negative patients displayed increased sFlt1 expression opposed to CTC positive breast cancer patients. Furthermore, significant enhanced PIGF values were also disclosed in CTC negative patients compared to patients being CTC positive. Analyzing the living patient collective we found significant differences in sFlt1 and PlGF values in regard to CTC negative and CTC positive patients.

conclusionBoth vascular markers showed enhanced expression in the CTC negative patient collective. To continue, the collective graded G2 showed significantly enhanced sFlt1 expressions amongst patients with no CTCs. Moreover, the patient collective with no lymph node metastasis and CTC negativity indicated statistically significant increased sFlt1 values. A functional interaction of sFlt1 and PlGF was found, suggesting that their overexpression in tumour cells inhibits CTCs entering the peripheral blood. Furthermore, in regard to CTC negativity, sFlt1 and PlGF values may potentially serve as predictive markers.

trial registrationThe TRN of this study is NCT02181101 and the date of registration was the 4(th) of June 2014. The study was retrospectively registered.

Indexed as

Up-RegulationBreast NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansNeoplasm MetastasisNeoplasm StagingNeoplastic Cells, CirculatingPlacenta Growth FactorRetrospective StudiesSurvival AnalysisVascular Endothelial Growth Factor Receptor-1FLT1 protein, humanPGF protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Breast cancerPlGFsFLT1Vascular markers

Identifiers

PMID27464822
PMCPMC4964055
OpenAlexW2485929674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.